CAMP and ovarian cancer: Using anti-LL-37 antibody to neutralize LL-37 in vivo can notably partly decrease the implantation of MSCs into ovarian cancer modeled by OVCAR-3 ovarian cancer cells, causing suppression of tumor growth and breakdown of the fibrovascular network.